Overview

A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment

Status:
Recruiting

Trial end date:
2024-12-11

Target enrollment:

Participant gender:

Summary

This is a Phase III, multicenter, randomized, open-label study designed to evaluate the efficacy and safety of atezolizumab given in combination with cabozantinib versus cabozantinib alone in participants with inoperable, locally advanced, or metastatic renal cell carcinoma (RCC) who experienced radiographic tumor progression during or after Immune Checkpoint Inhibitor (ICI) treatment in the metastatic setting.

Phase:

Phase 3

Details

Lead Sponsor:

Hoffmann-La Roche

Collaborators:

Chugai
Exelixis

Treatments:

Antibodies, Monoclonal
Atezolizumab